The medical technology company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.28 by $0.48, FiscalAI reports. , with pro forma adjusted constant-currency revenue growth of 4.7% and adjusted EPS of $1.76, supported by strong vascular and surgical performance. Teleflex provided fiscal 2026 adjusted EPS guidance of $6.90-$7.20, compared with the $6.70 analyst consensus. Teleflex Reports Second Quarter Results and Full-Year OutlookTeleflex provided fiscal 2026 adjusted EPS guidance of $6.90-$7.20, compared with the $6.70 analyst consensus. GAAP diluted EPS from continuing operations was $0.96, down from $1.54 a year earlier, despite the adjusted EPS beat.